2008
The Impact of Episodic CD4 Cell Count-Guided Antiretroviral Therapy on Quality of Life
Burman WJ, Grund B, Roediger MP, Friedland G, Darbyshire J, Wu AW. The Impact of Episodic CD4 Cell Count-Guided Antiretroviral Therapy on Quality of Life. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2008, 47: 185-193. PMID: 17971716, DOI: 10.1097/qai.0b013e31815acaa4.Peer-Reviewed Original ResearchConceptsQuality of lifeEpisodic antiretroviral therapyAntiretroviral therapyDisease progressionQoL assessmentTherapy groupInferior QOLMedian CD4 lymphocyte countContinuous therapy groupExcellent general healthCD4 cell countCD4 lymphocyte countCells/mm3HIV disease progressionCurrent healthAntiretroviral Therapy studyTherapy armMean followContinuous therapyLymphocyte countAnalog scaleQOL outcomesGeneral healthQOL instrumentsQoL comparisons
2005
The Role of Substance Abuse in HIV Disease Progression: Reconciling Differences from Laboratory and Epidemiologic Investigations
Kapadia F, Vlahov D, Donahoe RM, Friedland G. The Role of Substance Abuse in HIV Disease Progression: Reconciling Differences from Laboratory and Epidemiologic Investigations. Clinical Infectious Diseases 2005, 41: 1027-1034. PMID: 16142670, DOI: 10.1086/433175.Peer-Reviewed Original ResearchConceptsHIV disease progressionDisease progressionEpidemiologic investigationsHIV/AIDS epidemicUse of licitEpidemiological studiesSubstance abuseStudy designDrug abuseAIDS epidemicCareful evaluationReview of findingsProgressionIllicit drugsLaboratory-based studiesMethodological strengthsFindingsAbuseMixed results
2003
Use of Total Lymphocyte Count for Monitoring Response to Antiretroviral Therapy
Schreibman T, Friedland G. Use of Total Lymphocyte Count for Monitoring Response to Antiretroviral Therapy. Clinical Infectious Diseases 2003, 38: 257-262. PMID: 14699459, DOI: 10.1086/380792.Peer-Reviewed Original ResearchConceptsTotal lymphocyte countCD4 cell countAntiretroviral therapyCell countLymphocyte countHuman immunodeficiency virus (HIV) diseaseOpportunistic infection prophylaxisPotential surrogate markerResource-limited settingsHIV diseaseInfection prophylaxisLaboratory markersOpportunistic infectionsSurrogate markerDisease progressionClinical utilityImmune functionTherapeutic interventionsTherapyKey laboratory measurementsMonitoring responseVirus diseaseLack of availabilityDiseaseCount
1993
Association of Baseline Neuropsychological Function and Progression of Illness Over 4 Years in HIV-Seropositive Individuals
Silberstein C, O’dowd M, Schoenbaum E, Friedland G, Chartock P, Feiner C, Mckegney F. Association of Baseline Neuropsychological Function and Progression of Illness Over 4 Years in HIV-Seropositive Individuals. Journal Of The Academy Of Consultation-Liaison Psychiatry 1993, 34: 502-505. PMID: 8284340, DOI: 10.1016/s0033-3182(93)71824-1.Peer-Reviewed Original ResearchConceptsHuman immunodeficiency virus (HIV) disease progressionHIV-positive asymptomatic patientsCentral nervous system impairmentHIV-seropositive individualsNervous system impairmentBaseline neuropsychological functionProgressive HIVAsymptomatic HIVAsymptomatic patientsPoorer baseline scoresImmunologic dysfunctionSystemic symptomsDisease progressionNeuropsychological dysfunctionBaseline scoresNeuropsychological functionHIVPatientsSystem impairmentStudy periodNeuropsychological testsNeuropsychological markersDysfunctionProgressionHigher scores
1992
Clinical Manifestations and Predictors of Disease Progression in Drug Users with Human Immunodeficiency Virus Infection
Selwyn P, Alcabes P, Hartel D, Buono D, Schoenbaum E, Klein R, Davenny K, Friedland G. Clinical Manifestations and Predictors of Disease Progression in Drug Users with Human Immunodeficiency Virus Infection. New England Journal Of Medicine 1992, 327: 1697-1703. PMID: 1359411, DOI: 10.1056/nejm199212103272401.Peer-Reviewed Original ResearchMeSH KeywordsAcquired Immunodeficiency SyndromeAdultAIDS-Related Opportunistic InfectionsBacterial InfectionsCandidiasis, OralCD4-Positive T-LymphocytesFemaleFollow-Up StudiesHIV InfectionsHumansLeukocyte CountMaleMultivariate AnalysisNew York CityProportional Hazards ModelsProspective StudiesRacial GroupsSubstance Abuse, IntravenousZidovudineConceptsHuman immunodeficiency virus (HIV) infectionImmunodeficiency virus infectionDevelopment of AIDSInjection drug usersBacterial infectionsDisease progressionOral candidiasisVirus infectionSite primary medical careMultiple constitutional symptomsPyogenic bacterial infectionsHIV-seropositive patientsPercentage of CD4Cohort of patientsDiagnosis of AIDSMethadone treatment programsProportional hazards regressionProduct-limit survival analysisIncidence of AIDSPrimary medical careRate of progressionRisk of AIDSSeronegative patientsConstitutional symptomsSeropositive patients